Syndax Pharmaceuticals (SNDX) AI Stock Analysis

• Market Cap: $1.77B
• Dividend Yield: N/A
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: 597.19%
• EPS Growth: 0.45%
• Country: US
• Employees: 270
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.70
• Shares Outstanding: 86,914,840
• 10 Day Avg. Volume: 1,080,224
• 30 Day Avg. Volume: 1,132,538
• PEG Ratio: -0.14
• Price to Book (P/B): 3.93
• Price to Sales (P/S): 47.80
• P/FCF Ratio: -4.12
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 17.87
• Enterprise Value/Gross Profit: 19.36
• Enterprise Value/Ebitda: -6.76
• 1Y Price Target: $39.11
• Price Target Upside: 92.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $22.00 ▲(8.32% Upside)

The score is held back primarily by weak financial performance—large operating losses, heavy cash burn, and increased leverage—despite strong revenue growth and attractive gross margins. Offsetting this, technical trends are positive and recent earnings/corporate updates highlight meaningful commercial momentum and market expansion following FDA approval.

Positive Factors

Product Launch Success

The successful launch of Revuforj indicates strong market demand and effective commercialization, which can drive future revenue growth and enhance market position in oncology.

Strong Financial Position

The substantial upfront payment from Royalty Pharma bolsters Syndax's financial stability, providing resources to fund operations and support R&D, crucial for sustaining long-term growth.

FDA Approvals

FDA approvals for two first-in-class medicines enhance Syndax's competitive edge, enabling entry into new markets and potential revenue streams, critical for long-term success in the biotech industry.

Negative Factors

Declining Revenue

The significant decline in revenue highlights challenges in sustaining growth and profitability, necessitating strategic adjustments to stabilize financial performance and ensure long-term viability.

Negative Cash Flow

Persistent negative cash flow indicates financial strain, limiting Syndax's ability to fund operations internally, which could hinder growth initiatives and require external financing.

Market Penetration Challenges

Limited market penetration for Revuforj suggests difficulties in scaling sales and achieving widespread adoption, which may impact revenue potential and competitive positioning.

Syndax Pharmaceuticals Business Overview & Revenue Model

Company Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

How the Company Makes Money

Syndax Pharmaceuticals makes money through the development and commercialization of its drug candidates, primarily focusing on oncology treatments. The company's revenue model is centered around advancing its pipeline products through clinical trials, gaining regulatory approval, and eventually marketing these therapies to healthcare providers and patients. Revenue is generated from product sales, potential licensing agreements, and strategic partnerships with other pharmaceutical companies. These partnerships often provide upfront payments, milestone payments, and royalties as the products progress through development and reach the market. Significant factors contributing to its earnings include successful clinical trial results, regulatory approvals, and effective commercialization strategies.

Syndax Pharmaceuticals Financial Statement Overview

Summary

Strong top-line momentum (TTM revenue ~$111.6M, +42.7%) and very high gross margin (~95%) are positives, but they are outweighed by deeply negative profitability (net margin ~-279%), very large cash burn (TTM operating and free cash flow about -$311M), and meaningfully higher leverage (debt ~$345M vs equity ~$115M; ~3.0x debt-to-equity).

Income Statement

TTM (Trailing-Twelve-Months) revenue improved to ~$111.6M with strong growth (+42.7%) and very high gross margin (~95%), indicating attractive unit economics on current sales. However, profitability remains weak: EBIT and net income are deeply negative (net margin ~-279%), reflecting a cost structure that still far exceeds revenue. Compared with 2024 annual results, losses remain large despite the revenue step-up, highlighting ongoing execution risk until operating expenses scale down versus sales.

Balance Sheet

Leverage has increased materially: total debt is ~$345M while equity has declined to ~$115M in TTM (Trailing-Twelve-Months), pushing debt-to-equity to ~3.0x versus ~1.2x in 2024 and near-zero in 2022–2023. Total assets are still sizable (~$552M), but the sharp equity erosion and very negative return on equity signal that continued losses are pressuring the capital base and raising financing/refinancing risk if cash burn persists.

Cash Flow

Cash generation is a key weakness: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both about -$311M, indicating substantial cash burn. Free cash flow has worsened versus prior years (more negative than 2024 and 2023), and cash outflows broadly track net losses (free cash flow roughly in line with net income), suggesting limited near-term relief without either a step-change in revenue or meaningful cost reduction.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	111.55M	23.68M	0.00	0.00	139.71M	1.52M
Gross Profit	103.01M	22.85M	0.00	0.00	139.71M	1.52M
EBITDA	-294.81M	-313.82M	-209.14M	-146.17M	26.87M	-70.29M
Net Income	-311.58M	-318.76M	-209.36M	-149.34M	24.93M	-73.07M
Balance Sheet
Total Assets	551.79M	724.82M	612.88M	497.24M	449.66M	300.61M
Cash, Cash Equivalents and Short-Term Investments	454.17M	582.91M	577.58M	484.40M	446.83M	293.06M
Total Debt	345.43M	345.74M	1.64M	1.16M	20.97M	20.54M
Total Liabilities	436.36M	436.69M	58.68M	29.79M	41.29M	48.42M
Stockholders Equity	115.43M	288.12M	554.20M	467.45M	408.37M	252.19M
Cash Flow
Free Cash Flow	-311.01M	-274.90M	-160.60M	-133.90M	29.00M	-71.26M
Operating Cash Flow	-310.88M	-274.90M	-160.60M	-133.68M	29.13M	-71.26M
Investing Cash Flow	-60.52M	-219.78M	117.61M	-186.19M	-40.87M	-142.53M
Financing Cash Flow	355.18M	353.37M	264.13M	172.25M	118.46M	304.42M

Syndax Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 20.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNDX, the sentiment is Neutral. The current price of 20.31 is below the 20-day moving average (MA) of 20.81, above the 50-day MA of 20.28, and above the 200-day MA of 14.69, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 47.74 is Neutral, neither overbought nor oversold. The STOCH value of 31.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SNDX.

Syndax Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUVB	59 Neutral	$1.80B	-8.19	-52.49%	―	1137.19%	70.51%
KALV	57 Neutral	$789.03M	-3.90	―	―	―	-13.14%
SNDX	55 Neutral	$1.77B	-5.62	-129.32%	―	597.19%	0.45%
GERN	52 Neutral	$874.55M	-11.40	-29.57%	―	522.13%	62.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	49 Neutral	$1.31B	―	-308.02%	―	196.42%	53.92%
QURE	46 Neutral	$1.40B	-5.18	-165.27%	―	-44.90%	11.49%

Syndax Pharmaceuticals Corporate Events

Syndax Highlights Strong 2025 Results and Path to Profitability

On January 12, 2026, Syndax Pharmaceuticals reported preliminary, unaudited financial results for the fourth quarter and full year 2025, highlighting strong commercial uptake of its two recently launched products and progress toward profitability. Revuforj generated approximately $44 million in net revenue in the fourth quarter and $125 million for 2025, with a 38% sequential quarterly revenue increase following its October 24, 2025 FDA approval in relapsed or refractory NPM1-mutant AML and a roughly 35% rise in prescriptions, while also earning the 2025 Scrip Awards “Best New Drug” accolade and advancing into multiple Phase 3 and access-expansion programs. Niktimvo delivered about $56 million in fourth-quarter and $152 million in full-year 2025 net revenue, from which Syndax expects to recognize 25–30% as its share of net revenue when full-year results are reported, underpinning a growing royalty and profit-share stream from its collaboration with Incyte. The company ended 2025 with roughly $394 million in cash, cash equivalents and marketable securities and guided to about $400 million in 2026 operating expenses (excluding non-cash stock compensation), stating that its current cash plus anticipated product revenue and interest income are expected to fund operations through the transition to profitability, while it prioritizes revenue growth from Revuforj and Niktimvo and executes on a broad set of 2026 clinical milestones, including Phase 2 and Phase 3 trials in idiopathic pulmonary fibrosis and frontline acute leukemia.

The most recent analyst rating on (SNDX) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.

Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance

On December 18, 2025, the Board of Directors of Syndax Pharmaceuticals approved amendments to the company’s Amended and Restated Bylaws that change how its capital stock is issued and documented. Effective that date, all newly issued shares will be in uncertificated form, while any shares already represented by physical certificates before December 18, 2025, will remain certificated until those certificates are surrendered to the company, signaling a shift toward a fully electronic share record-keeping system that may streamline corporate administration and modernize shareholder documentation practices.

The most recent analyst rating on (SNDX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.

Syndax Pharmaceuticals Gains FDA Approval for Revuforj

On October 24, 2025, Syndax Pharmaceuticals announced that the FDA approved Revuforj® (revumenib) for treating relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in patients aged one year and older. This approval marks the first and only FDA-approved therapy for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation, solidifying Syndax’s leadership in menin inhibition. The approval is based on data from the AUGMENT-101 trial, which showed a 23% complete remission rate. Revuforj’s inclusion in the NCCN Guidelines and its availability through Syndax’s network of specialty distributors highlights its potential to become a new standard of care for these aggressive blood cancers.

The most recent analyst rating on (SNDX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.